Bespoke Extracts Inc (BSPK) Gross Profit Margin starting from the third quarter 2025 to third quarter 2024, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket
 


Bespoke Extracts Inc  (BSPK)


Bespoke Extracts Inc's Gross Profit Margin by quarter

Trends, Rankings, Statistics



BSPK Gross Profit Margin (Sep 30 2025)
Q3
(Jun 30 2025)
Q2
(Mar 31 2025)
Q1
(Dec 31 2024)
Q4
(Sep 30 2024)
Q3
Y / Y Revenue Change 68.63 %
Seq. Revenue Change 19.8 %
Revenue In Millions $0.47
Gross Profit Margin 50.05 %
Gross Profit Margin Total Ranking # 1689
Gross Profit In Millions $0.23
Y / Y Gross Profit Change 103.66 %
Seq. Gross Profit Change 18.58 %


Commenting Third Quarter 2025 Gross Profit Margin
Bespoke Extracts Inc has managed to improve its Revenue sequentially to $0.47 millions by 19.8 % faster than Gross Profit increase of 18.58 % to $0.23 millions, this led to contraction in Gross Profit Margin to 50.05 %, but the Bespoke Extracts Inc III. Quarter Gross Profit Margin remained above company average rate of 49.51%.


Observing third quarter 2025 results within Major Pharmaceutical Preparations industry 106 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to 1689, from total ranking in the previous quarter at 2102.
Learn about Gross Margin
BSPK's Gross Profit Margin third quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 107
Healthcare Sector # 314
Overall # 1671

Gross Profit Margin Statistics
High Average Low
72.85 % 49.51 % 11.63 %
(Nov 30 2020)   (Mar 31 2023)




Other Gross Profit Margin Profitability Ratios
BSPK's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
BSPK's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for BSPK's Competitors
Gross Profit Margin Profit Margin for Bespoke Extracts Inc's Suppliers
Gross Profit Margin Profit Margin for BSPK's Customers

You may also want to know
BSPK's Annual Growth Rates BSPK's Profitability Ratios BSPK's Asset Turnover Ratio BSPK's Dividend Growth
BSPK's Roe BSPK's Valuation Ratios BSPK's Financial Strength Ratios BSPK's Gross Profit Growth
BSPK's Roa BSPK's Inventory Turnover Ratio BSPK's Growth Rates BSPK's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Sep 30 2025, within Major Pharmaceutical Preparations Industry Gross Profit MarginSep 30 2025 MRQ Gross ProfitSep 30 2025 MRQ Revenue
Lexaria Bioscience Corp   100.00 %$ 0.174  Millions$ 0.174  Millions
Lexicon Pharmaceuticals Inc   99.93 %$ 14.172  Millions$ 14.182  Millions
Zai Lab Limited  99.90 %$ 115.976  Millions$ 116.095  Millions
Ptc Therapeutics inc   99.76 %$ 210.507  Millions$ 211.007  Millions
Kaya Holdings Inc   99.30 %$ 0.005  Millions$ 0.005  Millions
Travere Therapeutics Inc   99.04 %$ 163.274  Millions$ 164.859  Millions
Adc Therapeutics Sa  98.56 %$ 16.190  Millions$ 16.427  Millions
Ionis Pharmaceuticals Inc   98.51 %$ 154.381  Millions$ 156.719  Millions
Royalty Pharma Plc  98.01 %$ 597.156  Millions$ 609.291  Millions
Corcept Therapeutics Inc  97.79 %$ 203.042  Millions$ 207.638  Millions
Verastem Inc   97.42 %$ 10.952  Millions$ 11.242  Millions
Scienture Holdings Inc   97.39 %$ 0.575  Millions$ 0.590  Millions
One World Products Inc   97.25 %$ 0.049  Millions$ 0.050  Millions
Verrica Pharmaceuticals Inc   97.21 %$ 13.944  Millions$ 14.344  Millions
Ardelyx inc   96.39 %$ 106.347  Millions$ 110.329  Millions
Rafael Holdings Inc  96.25 %$ 0.231  Millions$ 0.240  Millions
Liquidia Corporation  95.78 %$ 52.047  Millions$ 54.342  Millions
Zevra Therapeutics Inc   95.25 %$ 24.825  Millions$ 26.063  Millions
Karyopharm Therapeutics Inc   95.20 %$ 41.931  Millions$ 44.044  Millions
Vanda Pharmaceuticals Inc   94.75 %$ 53.304  Millions$ 56.258  Millions
Avadel Pharmaceuticals Plc  94.69 %$ 73.351  Millions$ 77.467  Millions
Gyre Therapeutics Inc   94.67 %$ 28.936  Millions$ 30.564  Millions
Kyntra Bio Inc   94.61 %$ 1.018  Millions$ 1.076  Millions
Bridgebio Pharma Inc   94.56 %$ 114.137  Millions$ 120.700  Millions
Rigel Pharmaceuticals Inc  93.16 %$ 64.709  Millions$ 69.462  Millions
Axsome Therapeutics Inc   93.03 %$ 159.080  Millions$ 170.992  Millions
Ligand Pharmaceuticals Incorporated  92.99 %$ 107.364  Millions$ 115.461  Millions
Regeneron Pharmaceuticals Inc   92.52 %$ 3,473.300  Millions$ 3,754.300  Millions
Acadia Pharmaceuticals Inc   92.23 %$ 256.986  Millions$ 278.633  Millions
Arcutis Biotherapeutics Inc   91.25 %$ 90.534  Millions$ 99.219  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.